Sandoz launches the first generic version of Hectorol®

Princeton, New Jersey, February 5, 2014 – Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol®.

Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.1

“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” said Peter Goldschmidt, President of Sandoz Inc.

Sandoz is marketing …

/by

Sandoz recognizes World Cancer Day 2014

February 4, 2014 – Today Sandoz recognizes World Cancer Day. Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008, according to the World Health Organization. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030.

The high cost of treating cancer can be a significant barrier to patients. Well over half of all cancer deaths (70%) in 2008 occurred in low- and middle-income countries, according to the World Health Organization. Sandoz oncology injectables …

/by

Bulgaria approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, February 4, 2014 – Sandoz announced today it has received Bulgarian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

In January, 2014 Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden, Hungary and …

/by

Novartis announces Q4/Full Year 2013 results

Basel, January 29, 2014 – Novartis delivers strong sales and innovation in 2013; underlying business performance reinforces growth prospects.

Read the media release

…
/by

Romania approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …

/by

Romania approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 29, 2014 – Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Earlier this month, Sandoz also received marketing authorizations for AirFluSal® Forspiro® in Germany, Sweden and Hungary. …

/by

Novartis recognized among world’s most sustainable companies in Corporate Knights Global 100

Basel, January 27, 2014 – Novartis is pleased to announce that it has been named among the 2014 Corporate Knights Global 100.

Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index today at the World Economic Forum in Davos.

“Our inclusion in the Global 100 list is a testimony to our longstanding commitment to corporate responsibility,” said Joseph Jimenez, CEO of Novartis. “Being recognized among the top 100 sustainability performers in the world underscores that doing business responsibly …

/by

Sandoz launches Airflusal ® Forspiro® in Denmark

Copenhagen, January 20, 2014 – Sandoz announces that it is launching in Denmark today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.

Today’s launch in Denmark follows the announcement on December 18 that Sandoz had received its first EU market authorization for AirFluSal® Forspiro® after the completion the EU regulatory …

/by
Hungary approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 16, 2014 – Sandoz announced it has received marketing authorization in Hungary for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013 with subsequent marketing authorizations received earlier this week also in Germany and Sweden.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Hungary has approved the 50- …

/by

Sweden approves Sandoz’s Airflusal® Forspiro®

Holzkirchen, Germany, January 14, 2014 – Sandoz announced today it has received Swedish marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device. On January 13, 2014 Sandoz also received marketing authorization for AirFluSal® Forspiro® in Germany.

Sweden has approved the …

/by